Anna M. Tallman

Mar 14, 2023 | manchestertimes.com | Alexandra K. Golant |Rocco Serrao |Anna M. Tallman |Philip Brown

LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Mar 10, 2023--Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that data from multiple studies of VTAMA ® (tapinarof) cream, 1% will be presented at the 2023 American Academy of Dermatology Annual Meeting, to be held from March 17-21 in New Orleans, Louisiana.

Mar 13, 2023 | jofskin.org | Robert Bissonnette |Anna M. Tallman

1. Armstrong AW, et al. J Am Acad Dermatol. 2017;76:290–298. 2. Pathirana D, et al. J Eur Acad Dermatol Venereol. 2009;23:5–70. 3. Mahil SK, et al. Br J Dermatol. 2020;182:1158–1166. 4. Strober BE, et al. Dermatol Ther. 2019;9:5–18. 5. Bagel J and Stein Gold L. J Drugs Dermatol. 2017;16:1209–1222. 6. Armstrong A, et al. J Eur Acad Dermatol Venereol. 2018;32:2200–2207. 7. Elmets CA, et al. J Am Acad Dermatol. 2021;84:432-470. 8. Dermavant Sciences. VTAMA (tapinarof) cream, 1%: US prescribing information. 2022.

Mar 10, 2023 | finanznachrichten.de | Alexandra K. Golant |Rocco Serrao |Anna M. Tallman |Philip Brown

- Three presentations, including two orals, will highlight the efficacy, tolerability and pharmacokinetics of VTAMA cream for the treatment of adults with plaque psoriasis Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that data from multiple studies of VTAMA(tapinarof) cream, 1% will be presented at the 2023 American Academy of Dermatology Annual Meeting, to be held from March 17-21 in...